Ixazomib(Ninlaro)

Ixazomib is a prescription drug that targets protein kinase C delta (PKCδ). It was approved for marketing by the U.S. Food and Drug Administration (FDA) on November 20, 2015, and must be used strictly in accordance with the doctor’s instructions.

Lucius Related Certificates

Drug Testing Report

Drug Approval Certificate

Target of Action

Protein Kinase C delta (PKCδ).

Mechanism of Action

Ixazomib is a small-molecule drug that can penetrate myeloma cells and bind to the proteasome. Once it binds to the intracellular proteasome, it will slow down or block the proteasome from performing its function of clearing damaged proteins.

Inhibition of proteasome activity by ixazomib leads to the accumulation of proteins within the cell, which in turn induces the death of myeloma cells.

Dosage and Administration

Route of Administration and Frequency of Ixazomib: The recommended starting dose is 4 mg, administered orally once weekly.

The dosage of ixazomib needs to be adjusted according to the patient’s actual condition. For specific details, patients should consult their doctors and strictly follow the medical instructions.

Recommended Reading: Dosage and Administration of Ixazomib

Adverse Reactions

Most common adverse reactions (≥20%): thrombocytopenia, neutropenia, diarrhea, etc.

Severe adverse reactions: diarrhea, thrombocytopenia, bronchitis.

Reference Article: Adverse Reactions of Ixazomib

Medication Use in Special Populations

Lactation: It is recommended that women should not breastfeed during treatment with Ninlaro and for 90 days after the last dose.

Hepatic Impairment: For patients with moderate or severe hepatic impairment, the starting dose of Ninlaro should be reduced to 3 mg.

Renal Impairment: For patients with severe renal impairment or end-stage renal disease requiring dialysis, the starting dose of Ninlaro should be reduced to 3 mg. Ninlaro cannot be removed by dialysis.

Precautions for Daily Use

1. For your safety, Ixazomib (NINLARO) is sealed in a protective medication box. You and your healthcare team should not remove the drug from the packaging until immediately before administration.

2. Avoid direct contact with the powder inside the capsules.

3. If the powder from ixazomib capsules accidentally contacts the skin, immediately wash the contaminated area thoroughly with soap and water.

from FDA,2024.07